Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

Learn about the practical use of Suliqua®(insulin glargine 100 units/mL and lixisenatide) for the treatment of type 2 diabetes in adults

Despite current guideline recommendations for people with type 2 diabetes,1,2 treatment often remains suboptimal, with many patients failing to achieve glycaemic targets over time.3,4 When treatment intensification with multiple therapies is required, use of combination products may simplify regimens and aid compliance.5

This website aims to provide healthcare professionals with advice and practical information about Suliqua, a once-daily, titratable, fixed-ratio combination of basal insulin glargine 100 Units/mL and the glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide. Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.6 We hope that you will find the resources on this website useful in your everyday clinical practice.

Video resources

UK healthcare professionals discuss the use of Suliqua in everyday clinical practice

Play Video

Watch the presentations from the webcast broadcast on 5 May 2021

VIDEO

Play Video

Practical use of Suliqua for the management of people with type 2 diabetes

Amar Ali, GP, Blackburn

VIDEO

Play Video

Outlining the rationale for fixed ratio combination therapy

Amar Ali, GP, Blackburn

VIDEO

Play Video

Improving glycaemic outcomes in uncontrolled high risk type 2 diabetes: Frequently asked questions

Ed Jude, Consultant in Diabetes and Endocrinology, Tameside Hospital NHSFoundation Trust

VIDEO

Play Video

Improving glycaemic outcomes in uncontrolled high risk type 2 diabetes: Frequently asked questions

Grace Vanterpool, Nurse Consultant, Diabetes, West London NHS Trust

VIDEO

Print materials

This advertorial aims to outline key aspects of the efficacy and
safety of Suliqua from the Phase III clinical trial data as well as providing practical advice on its initiation and titration.

Amar Ali, a GP with a special interest in diabetes from Blackburn, shares his own personal experience of using Suliqua in patients treated in primary care, along with hints and tips for its use in this context.

Learn more about Suliqua

For more information on Suliqua, such as patient support, dosing and titration guides, videos and further evidence
References 1. Buse JB, et al (2020) Diabetes Care 43:487–93
2. NICE (2015). Type 2 diabetes in adults: management (NG28). Available at: https://www.nice.org.uk/guidance/ng28 (accessed May 2021)
3. Khunti K et al (2013) Diabetes Care 36:3411–7

4. Khunti K, Millar-Jones DM (2017) Prim Care Diab 11:3–12
5. Skolnik N, et al (2017) Curr Med Res Opin 33:2187–94
6. Suliqua Summary of Product Characteristics. Available at:
https://www.medicines.org.uk/emc/product/9871/smpc (accessed May 2021)

The resources on this website have been initiated and fully funded by Sanofi.
They have been reviewed and approved by the sponsoring company prior to publication.
Editorial support was provided by OmniaMed Communications.

Job code: MAT-GB-2101129 (v2.0) | July 2021

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.